Correspondence Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients

AIDS

Volumn 22, Issue 18, 2008, Pages 2549-2551

  Cabrera, Salvador E ^a   Cordero, Miguel ^b   Iglesias, Alicia ^a   Valverde, María P ^c   Gil, Alfonso Domínguez ^b   García, María J ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN; PYRAZINAMIDE; RIFAMPICIN; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT;

ADULT; CASE REPORT; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERACTION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MILIARY TUBERCULOSIS; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; VIRUS LOAD; MIDDLE AGED; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; BENZOXAZINES; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 57349103074     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283189c07     Document Type: Letter

References (7)

1. Soy D, Lopez E, Sarasa M, Lopez-Pua Y, Lopez-Cortes L, Ruiz- Valderas R, et al. Population pharmacokinetic modeling in HIV patients with tuberculosis treated with efavirenz and rifampicin [abstract #15]. In: 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada, 28-30 April 2005.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 29 January 2008. pp. 1-128. http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL. pdf. [Accessed 29 May 2008].
3. Updated Guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2004;53:37.
4. American Thoracic Society; Centers for Disease Control; Infectious Disease Society of America. Treatment of tuberculosis. MMWR 2003;52:1-77.
5. Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study Group. AIDS 2002;16:605-613.
6. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-75.
7. Joly V, Yeni P. Non nucleoside reverse transcriptase inhibitors. AIDS Rev 1999;1:37-44.